Advances in Cancer Research: Sphingolipids in Cancer: Vol 140
Language: English
Published by Academic Pr, 2018
Series: Book 7 of 13 - ISSN
- Hardcover
- New
Seller: Revaluation Books, Exeter, United KingdomRevaluation Books
AbeBooks seller since January 6, 2003
Condition: New
£ 131.95
Quantity: 2 available
Add to basketItem description from seller
1st edition. 388 pages. 9.00x6.00x1.00 inches. In Stock.
Seller Inventory # __0128142235
- Title
- Advances in Cancer Research: Sphingolipids in Cancer: Vol 140
- Author
- Tew, Kenneth D. (Editor)/ Chalfant, Charles (Editor)/ Fisher, Paul B. (Editor)
- Publisher
- Academic Pr
- Publication year
- 2018
- Condition
- Brand New
- Binding
- Hardcover
- Language
- English
- ISBN 10
- 0128142235
- ISBN 13
- 9780128142233
- Item weight
- 0.89 kilograms
- Series
- Book 7 of 13: ISSN
Sphingolipids in Cancer, Volume 140, the latest release in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. Topics discussed in this updated volume include Mechanisms of ceramide-dependent cancer cell death, Sphingolipids as regulators of autophagy and endocytic trafficking, The role and function of sphingomyelin biosynthesis in the development of cancer, Neutral sphingomyelinases in cancer: Friend or foe?, Sphingolipid rendezvous at the crossroad of NAFLD and senescence, Ceramide signaling and p53 pathways, Sphingolipid regulation of RNA Biology in cancer phenotypes, The role of ceramide-1-phosphate in tumor cell survival and dissemination, and more.
- Provides information on cancer research, with this release focusing on sphingolipids
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
"Synopsis" may belong to another edition of this title.
About the Author
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
"About the title" may belong to another edition of this title.
Revaluation Books
Exeter, United Kingdom
AbeBooks seller since January 6, 2003
Shipping rates from United Kingdom to U.S.A.
| Item | 7 to 14 business days | 2 to 3 business days |
|---|---|---|
| First item | £ 12.50 | £ 25.00 |
Payment methods
Seller's business information
Edward Bowditch Ltd
Exstowe, Exton
Exeter, United Kingdom EX3 0PP
Terms of sale
Legal entity name: Edward Bowditch Ltd
Legal entity form: Limited company
Business correspondence address: Exstowe, Exton, Exeter, EX3 0PP
Company registration number: 04916632
VAT registration: GB834241546
Authorised representative: Mr. E. Bowditch
Right of withdrawal
If you are a consumer you can withdraw from the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.
Information regarding the right of withdrawal
Statutory right to withdraw
You have the right to withdraw from this contract within 14 days without giving any reason.
The withdrawal period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the last good or the last lot or piece.
To exercise the right of withdrawal, electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". We will communicate to you an acknowledgement of receipt of such a withdrawal on a durable medium (e.g. by e-mail) without delay.
To meet the withdrawal deadline, it is sufficient for you to send your communication concerning your exercise of the right of withdrawal before the withdrawal period has expired.
Effects of withdrawal
If you withdraw from this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).
We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.
We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to withdraw from this contract.
We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.
We may withhold reimbursement until we have received the goods back, or you have supplied evidence of having sent back the goods, whichever is the earliest.
You shall send back the goods or hand them over to Revaluation Books, Hounslow, United Kingdom, without undue delay and in any event not later than 14 days from the day on which you communicate your withdrawal from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.
Exceptions to the right of withdrawal
The right of withdrawal does not apply to:
- The delivery of newspapers, journals or magazines with the exception of subscription contracts; and
- The supply of digital content which is not supplied on a tangible medium (e.g. on a CD or DVD) if you accepted when you placed your order that we could start to deliver it, and that you could not withdraw once delivery had started.
Shipping terms
Orders usually dispatched within two working days.